The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin
Abstract
We previously have found that advanced glycation end products (AGE), senescent macroproteins formed at an accelerated rate in diabetes, arise in vivo not only from glucose but also from reducing sugars. Furthermore, we recently have shown that glyceraldehyde‐ and glycolaldehyde‐derived AGE (glycer‐ and glycol‐AGE) are mainly involved in loss of pericytes, the earliest histopathological hallmark of diabetic retinopathy. However, the effects of these AGE proteins on angiogenesis, another vascular derangement in diabetic retinopathy, remain to be elucidated. In this study, we investigated whether these AGE proteins elicit changes in cultured endothelial cells that are associated with angiogenesis. When human skin microvascular endothelial cells (EC) were cultured with glycer‐AGE or glycol‐AGE, growth and tube formation of EC, the key steps of angiogenesis, were significantly stimulated. The AGE‐induced growth stimulation was significantly enhanced in AGE receptor (RAGE)‐overexpressed EC. Furthermore, AGE increased transcriptional activity of nuclear factor‐κB (NF‐κB) and activator protein‐1 (AP‐1) and then up‐regulated mRNA levels of vascular endothelial growth factor (VEGF) and angiopoietin‐2 (Ang‐2) in EC. Cerivastatin, a hydroxymethylglutaryl CoA reductase inhibitor; pyrrolidinedithiocarbamate; or curcumin was found to completely prevent the AGE‐induced increase in NF–κB and AP‐1 activity, VEGF mRNA up‐regulation, and the resultant increase in DNA synthesis in microvascular EC. These results suggest that the AGE‐RAGE interaction elicited angiogenesis through the transcriptional activation of the VEGF gene via NF‐κB and AP‐1 factors. By blocking AGE‐RAGE signaling pathways, cerivastatin might be a promising remedy for treating patients with proliferative diabetic retinopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
Nishikawa, T., Edelstein, D., Du, X. L., Yamagishi, S.-I., Matsumura, T., Kaneda, Y., Yorek, M. A., Beebe, D., Oates, P. J., Hammes, H.-P., et al. (2000) · Nature · doi:10.1038/35008121 · Cited by 4,277
Self-citationLander, H. M., Tauras, J. M., Ogiste, J. S., Hori, O., Moss, R. A., & Schmidt, A. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.28.17810 · Cited by 813
Cited by
Advanced Glycation End Products: Sparking the Development of Diabetic Vascular Injury
Goldin, A., Beckman, J. A., Schmidt, A. M., & Creager, M. A. (2006) · Circulation · doi:10.1161/circulationaha.106.621854 · Cited by 2,261
Role of advanced glycation end products in cellular signaling
Ott, C., Jacobs, K., Haucke, E., Navarrete Santos, A., Grune, T., & Simm, A. (2014) · Redox Biology · doi:10.1016/j.redox.2013.12.016 · Cited by 1,150
“cells Angiogenesis 100 mg/ml -Increased expression vascular endothelial growth factor (VEGF) and angiopoietin-2 [226]”
BackgroundBoulton, A. J. M., Malik, R. A., Arezzo, J. C., & Sosenko, J. M. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1458 · Cited by 913
van Beijnum, J. R., Buurman, W. A., & Griffioen, A. W. (2008) · Angiogenesis · doi:10.1007/s10456-008-9093-5 · Cited by 527
Hyperglycemia and Glycation in Diabetic Complications
Negre-Salvayre, A., Salvayre, R., Augé, N., Pamplona, R., & Portero-Otín, M. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2484 · Cited by 421
Metadata
- Authors
- Okamoto, T., Yamagishi, S., Inagaki, Y., Amano, S., Koga, K., Abe, R., Takeuchi, M., Ohno, S., Yoshimura, A., & Makita, Z.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2002-10-04
- Volume
- 16
- Issue
- 14
- Pages
- 1928-1930
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2133857970
- Cited by
- 258
- References
- 2
- FWCI
- 9.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. https://app.cochat.ai/papers/10.1096/fj.02-0030fje
- The paper
- Okamoto, T., Yamagishi, S., Inagaki, Y., Amano, S., Koga, K., Abe, R., Takeuchi, M., Ohno, S., Yoshimura, A., & Makita, Z. (2002). Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. The FASEB Journal. https://doi.org/10.1096/fj.02-0030fje
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.